Dyadic International
DYAINASDAQUSD
- Source valuation snapshot. Not a live recalculation.
- Latest filed annual earnings; price snapshot date unavailable. Not forward P/E.
- Diluted earnings per share from the latest filed annual.
- $0.35 Prior regular-session close from the quote source.
- $0.32–$0.35 Regular-session low and high so far today.
- 188.4K Regular-session shares traded · Nov 13, 4:00 PM ET.
- Feb 12 projected Projected for 2027-02-12 from the company’s own results filings (SEC 8-K Item 2.02). The company has not confirmed the date.
- $0.32–$1.60 52-week trading low and high returned by the quote source.
Understand the Business
Why the Stock Moved
Period-matched expectations history is not yet available. Current metrics are not a substitute for a historical explanation.
The core investment thesis
Own DYAI if DYAI is a high-risk licensing option on its biology-production technology becoming valuable enough for collaborators to fund, license, and commercialize before the company’s cash runway and partner-dependence become the limiting factors.
DYAI price history
Loading recent earnings…
Investment thesis
What must happen next
Collaborators and licensees must keep choosing DYAI’s technology over alternative production and development approaches, so partner activity converts into recurring licensing, service, milestone, or royalty revenue rather than one-off research work.HoldingMateriality: High
GAAP annual revenue was $3.09 million in FY2025, showing the company is still monetizing customer and collaborator arrangements. If partner adoption compounds, the asset-light platform can become valuable; if it does not, the business remains a small revenue base funding a larger R&D expense structure.
Watch: A major collaborator or licensee chooses a competing expression or biologics-production platform and ends DYAI-related development work.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual revenue was $3.09 million in FY2025, showing the company is still monetizing customer and collaborator arrangements.
Open source ↗The asset-light model works only if DYAI can maintain access to CROs and third-party service providers on acceptable terms; otherwise development delays or the need to build internal capacity would absorb capital before commercialization arrives.WeakeningMateriality: High
GAAP annual operating cash flow was negative $5.70 million in FY2025, confirming that outsourced development still consumes cash. Reliable outsourced execution lets DYAI preserve optionality; a CRO bottleneck would raise costs, delay partner programs, and increase financing risk.
Watch: A key CRO or service provider terminates service, refuses renewal, or prioritizes other customers, delaying DYAI research or manufacturing programs.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
GAAP annual operating cash flow was negative $5.70 million in FY2025, confirming that outsourced development still consumes cash.
Open source ↗DYAI needs a higher-value mix of licensing and collaboration economics, not merely more reimbursed or low-margin service work, because the platform must generate enough gross profit to help fund continued development.WeakeningMateriality: Medium
Estimated GAAP annual gross profit was $770,485 in FY2025, down sharply from $2.30 million in FY2024. Revenue that carries weak gross profit does not solve the funding problem; higher-quality licenses and milestones would make the same revenue base much more valuable.
Watch: Customer demand shifts toward low-margin contract research services rather than license fees, milestones, or royalties.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Estimated GAAP annual gross profit was $770,485 in FY2025, down sharply from $2.30 million in FY2024.
Open source ↗Because DYAI is still loss-making, the company must secure enough partner-funded work, milestones, licensing proceeds, or external financing to maintain development momentum without punitive dilution or balance-sheet stress.WeakeningMateriality: Medium
Cash was $4.62 million at FY2025 year-end, down from $6.51 million at FY2024 year-end. For shareholders, the platform option has value only if the company survives long enough to realize it on reasonable per-share terms.
Watch: No material new licensing, collaboration, milestone, or financing announcement arrives before the existing cash cushion is further depleted.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Cash was $4.62 million at FY2025 year-end, down from $6.51 million at FY2024 year-end.
Open source ↗DYAI’s ability to monetize its technology depends on keeping IP rights and collaboration relationships clear; disputes with Danisco, CROs, collaborators, or licensees would reduce future licensing opportunities before revenue visibly falls.HoldingMateriality: Medium
Item 1 specifically warns that disagreements with Danisco, CROs, collaborators, or licensees could develop over intellectual property rights or further licensing. For a licensing company, relationship and IP friction can impair the core asset even if near-term reported revenue has not yet rolled over.
Watch: Danisco asserts rights or restrictions that limit DYAI’s ability to license technology in pharmaceutical or other fields.
Supporting sources
Source notes are factual paraphrases; read the original disclosures below.
Item 1 specifically warns that disagreements with Danisco, CROs, collaborators, or licensees could develop over intellectual property rights or further.
Open source ↗
Full investment case & evidence
Loading the original research archive…
Original research
Collaborators and licensees must keep choosing DYAI’s technology over alternative production and development approaches, so partner activity converts into recurring licensing, service, milestone, or royalty revenue rather than one-off research work. If partner adoption compounds, the asset-light platform can become valuable; if it does not, the business remains a small revenue base funding a larger R&D expense structure.
The asset-light model works only if DYAI can maintain access to CROs and third-party service providers on acceptable terms; otherwise development delays or the need to build internal capacity would absorb capital before commercialization arrives. Reliable outsourced execution lets DYAI preserve optionality; a CRO bottleneck would raise costs, delay partner programs, and increase financing risk.
DYAI needs a higher-value mix of licensing and collaboration economics, not merely more reimbursed or low-margin service work, because the platform must generate enough gross profit to help fund continued development. Revenue that carries weak gross profit does not solve the funding problem; higher-quality licenses and milestones would make the same revenue base much more valuable.
Because DYAI is still loss-making, the company must secure enough partner-funded work, milestones, licensing proceeds, or external financing to maintain development momentum without punitive dilution or balance-sheet stress. For shareholders, the platform option has value only if the company survives long enough to realize it on reasonable per-share terms.
DYAI’s ability to monetize its technology depends on keeping IP rights and collaboration relationships clear; disputes with Danisco, CROs, collaborators, or licensees would reduce future licensing opportunities before revenue visibly falls. For a licensing company, relationship and IP friction can impair the core asset even if near-term reported revenue has not yet rolled over.
All standing thesis claims
Original report summary
DYAI is a high-risk licensing option on its biology-production technology becoming valuable enough for collaborators to fund, license, and commercialize before the company’s cash runway and partner-dependence become the limiting factors.
Bull case and bear case
Bull case and bear case for Dyadic International
Where the evidence on Dyadic International disagrees: Mixed on the latest evidence (Oct 15, 2026). Of its 5 thesis points, 2 holding and 3 weakening.
Bull case: what the evidence supports
Collaborators and licensees must keep choosing DYAI’s technology over alternative production and development approaches, so partner activity converts into recurring licensing, service, milestone, or royalty revenue rather than one-off research work.
DYAI’s ability to monetize its technology depends on keeping IP rights and collaboration relationships clear; disputes with Danisco, CROs, collaborators, or licensees would reduce future licensing opportunities before revenue visibly falls.
Bear case: what the evidence questions
The asset-light model works only if DYAI can maintain access to CROs and third-party service providers on acceptable terms; otherwise development delays or the need to build internal capacity would absorb capital before commercialization arrives.
DYAI needs a higher-value mix of licensing and collaboration economics, not merely more reimbursed or low-margin service work, because the platform must generate enough gross profit to help fund continued development.
Because DYAI is still loss-making, the company must secure enough partner-funded work, milestones, licensing proceeds, or external financing to maintain development momentum without punitive dilution or balance-sheet stress.
Thesis-Break Engine
Thesis-break watch · Dyadic International
No break has crossed Dyadic International’s thesis. Its break conditions are checked against every new filing as it lands.
MARKET + FINANCIAL SNAPSHOT
The numbers behind the thesis
What Changed
- MixedDelisting notice or listing-rule failure.
Dyadic International filed an SEC 8-K on 2026-09-25: Delisting notice or listing-rule failure. It is a dated development that tests the current thesis.
- MixedEntered a material definitive agreement.
Dyadic International filed an SEC 8-K on 2026-08-14: Entered a material definitive agreement. It is a dated development that tests the current thesis.
- MixedReported results of operations (earnings release).
Dyadic International filed an SEC 8-K on 2026-08-12: Reported results of operations (earnings release). It is a dated development that tests the current thesis.
Risks / falsifiers
What could break the thesis
- A major collaborator or licensee chooses a competing expression or biologics-production platform and ends DYAI-related development work.
- A key CRO or service provider terminates service, refuses renewal, or prioritizes other customers, delaying DYAI research or manufacturing programs.
- Customer demand shifts toward low-margin contract research services rather than license fees, milestones, or royalties.
- No material new licensing, collaboration, milestone, or financing announcement arrives before the existing cash cushion is further depleted.
- Danisco asserts rights or restrictions that limit DYAI’s ability to license technology in pharmaceutical or other fields.
DYAI news
Loading headlines…
Financial statements
DYAI income statement
Annual filed results · USD · Oldest to newest. Margins are calculated from the reported figures.
DYAI: quick answers
- When does Dyadic International (DYAI) report earnings next?
- Dyadic International's next results are projected for February 12, 2027, from the dates of its own results filings with the SEC. The company has not confirmed the date. It last reported on November 13, 2026. Earnings calendar
- What is DYAI's short interest?
- As of October 30, 2026, 83,236 DYAI shares were sold short, down 57.3% from the count before. At the stock's average daily volume that is 1.0 day to cover. FINRA publishes the count twice a month. DYAI short interest history

